Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D. to Board of Directors
September 28 2021 - 4:05PM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule single-agent and combination therapy
candidates for the treatment of non-alcoholic steatohepatitis
(NASH) and other chronic liver diseases, today announced the
appointment of Ann E. Taylor, M.D., to the Company’s Board of
Directors. Dr. Taylor previously served as the Chief Medical
Officer of AstraZeneca plc and brings to the Terns Board of
Directors more than 35 years of experience in drug development.
“NASH remains an area of significant unmet need and I believe
Terns’ approach, which seeks to combine best-in-class molecules
with clinically validated mechanisms in NASH, will play a
significant part in the treatment of NASH patients,” said Dr.
Taylor. “I am proud to join this strong and diverse team and look
forward to working with the rest of the board and the management
team in developing truly transformative medicines.”
“We are excited to have Ann join our board of directors and to
have access to her drug development expertise and network,” said
Senthil Sundaram, Chief Executive Officer of Terns. “Ann is a
seasoned drug development veteran who has a wealth of experience in
bringing treatments to patients across a broad spectrum of
challenging areas. The board and I look forward to Ann’s
contributions to Terns as we generate meaningful clinical data over
the coming months and years.”
Dr. Taylor served as the Chief Medical Officer of AstraZeneca
until her retirement in August 2021. Her broad-based leadership
experience includes clinical development, portfolio strategy,
regulatory strategy, biomarker strategy, patient safety and quality
assurance across AstraZeneca’s entire portfolio. Prior to becoming
Chief Medical Officer, from April 2018 to March 2019, Dr. Taylor
was the Head of Clinical Biologics at MedImmune, a wholly owned
subsidiary of AstraZeneca. Prior to AstraZeneca, Dr. Taylor held
various leadership roles at Novartis Institute for BioMedical
Research (Global Head of Portfolio Management, Interim Head of
Cardiovascular and Metabolic Disease Area, Global Head of
Translational Medicine for Metabolism) and Pfizer (Portfolio Lead
for Obesity, Frailty and Cardiovascular and Metabolic Disease
Franchise). Dr. Taylor also serves on the board of directors of
Unlearn.AI, a company seeking to accelerate clinical development
through the use of artificial intelligence. She has authored and
co-authored numerous peer-reviewed publications and served on the
editorial board of several peer-reviewed journals. Dr. Taylor is a
Board-certified endocrinologist and received her M.D. from Harvard
Medical School. She received her B.A. in biology magna cum laude
from the University of California, San Diego.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule single-agent and
combination therapy candidates for the treatment of non-alcoholic
steatohepatitis, or NASH, and other chronic liver diseases. Terns’
pipeline includes three clinical stage development programs
including an FXR agonist, a VAP-1 inhibitor and a THR-β agonist,
and a preclinical GLP-1 receptor agonist program. Terns is focused
on developing combination therapies based on clinically validated
and complementary mechanisms of action to address the multiple
hepatic disease processes of NASH in order to drive meaningful
clinical benefits for patients. For more information, please visit:
www.ternspharma.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Terns Pharmaceuticals, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the Company’s expectations of timing and
potential results of the Company’s clinical trials and other
development activities; the potential utility and progress of the
Company’s product candidates in NASH and other therapeutic areas;
the Company’s clinical development plans and activities; the
Company’s expectations regarding the profile of its product
candidates, including tolerability, safety, metabolic stability and
pharmacokinetic profile; and the Company’s ability to continue to
execute on its clinical strategy and plans. All statements other
than statements of historical facts contained in this press
release, including statements regarding the Company’s strategy,
future financial condition, future operations, future trial
results, projected costs, prospects, plans, objectives of
management and expected market growth, are forward-looking
statements. In some cases, you can identify forward-looking
statements by terminology such as “aim,” “anticipate,” “assume,”
“believe,” “contemplate,” “continue,” “could,” “design,” “due,”
“estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,”
“positioned,” “potential,” “predict,” “seek,” “should,” “target,”
“will,” “would” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of
these terms or other comparable terminology. The Company has based
these forward-looking statements largely on its current
expectations, estimates, forecasts and projections about future
events and financial trends that it believes may affect its
financial condition, results of operations, business strategy and
financial needs. In light of the significant uncertainties in these
forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events. These
statements are subject to risks and uncertainties that could cause
the actual results and the implementation of the Company’s plans to
vary materially, including the risks associated with the
initiation, cost, timing, progress and results of the Company’s
current and future research and development activities and
preclinical studies and clinical trials. In particular, the impact
of the COVID-19 pandemic on the Company’s ability to progress with
its research, development, manufacturing and regulatory efforts,
including the Company’s clinical trials for its product candidates,
will depend on future developments that are highly uncertain and
cannot be predicted with confidence at this time, such as the
ultimate duration of the pandemic, travel restrictions,
quarantines, social distancing and business closure requirements in
the United States and in other countries, and the effectiveness of
actions taken globally to contain and treat the disease. These
risks are not exhaustive. For a detailed discussion of the risk
factors that could affect the Company’s actual results, please
refer to the risk factors identified in the Company’s SEC reports,
including but not limited to its Annual Report on Form 10-K for the
year ended December 31, 2020 and its Quarterly Reports on Form 10-Q
for the periods ended March 31, 2021 and June 30, 2021. Except as
required by law, the Company undertakes no obligation to update
publicly any forward-looking statements for any reason.
Contacts for Terns
InvestorsJustin Nginvestors@ternspharma.com
MediaJenna UrbanBerry & Company Public
Relationsmedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Sep 2023 to Sep 2024